These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36807802)

  • 1. Manipulation of Murine Mitochondrial DNA Heteroplasmy with mtZFNs.
    Nash PA; Minczuk M
    Methods Mol Biol; 2023; 2615():329-344. PubMed ID: 36807802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Manipulation of Human Mitochondrial DNA Heteroplasmy In Vitro Using Tunable mtZFN Technology.
    Gammage PA; Minczuk M
    Methods Mol Biol; 2018; 1867():43-56. PubMed ID: 30155814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of mtZFNs into Early Mouse Embryos.
    McCann BJ; Cox A; Gammage PA; Stewart JB; Zernicka-Goetz M; Minczuk M
    Methods Mol Biol; 2018; 1867():215-228. PubMed ID: 30155826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered mtZFNs for Manipulation of Human Mitochondrial DNA Heteroplasmy.
    Gammage PA; Van Haute L; Minczuk M
    Methods Mol Biol; 2016; 1351():145-62. PubMed ID: 26530680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Manipulation of mtDNA Heteroplasmy: A Shifting Perspective.
    Jackson CB; Turnbull DM; Minczuk M; Gammage PA
    Trends Mol Med; 2020 Jul; 26(7):698-709. PubMed ID: 32589937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating Mitochondrial DNA Heteroplasmy with Mitochondrially Targeted Endonucleases.
    Mikhailov N; Hämäläinen RH
    Ann Biomed Eng; 2024 Sep; 52(9):2627-2640. PubMed ID: 36001180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo.
    Gammage PA; Viscomi C; Simard ML; Costa ASH; Gaude E; Powell CA; Van Haute L; McCann BJ; Rebelo-Guiomar P; Cerutti R; Zhang L; Rebar EJ; Zeviani M; Frezza C; Stewart JB; Minczuk M
    Nat Med; 2018 Nov; 24(11):1691-1695. PubMed ID: 30250142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations.
    Gammage PA; Rorbach J; Vincent AI; Rebar EJ; Minczuk M
    EMBO Mol Med; 2014 Apr; 6(4):458-66. PubMed ID: 24567072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manipulation of mitochondrial genes and mtDNA heteroplasmy.
    Bacman SR; Gammage PA; Minczuk M; Moraes CT
    Methods Cell Biol; 2020; 155():441-487. PubMed ID: 32183972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial DNA heteroplasmy in disease and targeted nuclease-based therapeutic approaches.
    Nissanka N; Moraes CT
    EMBO Rep; 2020 Mar; 21(3):e49612. PubMed ID: 32073748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Near-complete elimination of mutant mtDNA by iterative or dynamic dose-controlled treatment with mtZFNs.
    Gammage PA; Gaude E; Van Haute L; Rebelo-Guiomar P; Jackson CB; Rorbach J; Pekalski ML; Robinson AJ; Charpentier M; Concordet JP; Frezza C; Minczuk M
    Nucleic Acids Res; 2016 Sep; 44(16):7804-16. PubMed ID: 27466392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current strategies towards therapeutic manipulation of mtDNA heteroplasmy.
    Pereira CV; Moraes CT
    Front Biosci (Landmark Ed); 2017 Jan; 22(6):991-1010. PubMed ID: 27814659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altering the balance between healthy and mutated mitochondrial DNA.
    Smith PM; Lightowlers RN
    J Inherit Metab Dis; 2011 Apr; 34(2):309-13. PubMed ID: 20506041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease.
    Bayona-Bafaluy MP; Blits B; Battersby BJ; Shoubridge EA; Moraes CT
    Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14392-7. PubMed ID: 16179392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TALEN-mediated shift of mitochondrial DNA heteroplasmy in MELAS-iPSCs with m.13513G>A mutation.
    Yahata N; Matsumoto Y; Omi M; Yamamoto N; Hata R
    Sci Rep; 2017 Nov; 7(1):15557. PubMed ID: 29138463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs.
    Bacman SR; Williams SL; Pinto M; Peralta S; Moraes CT
    Nat Med; 2013 Sep; 19(9):1111-3. PubMed ID: 23913125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High throughput single cell analysis of mitochondrial heteroplasmy in mitochondrial diseases.
    Maeda R; Kami D; Maeda H; Shikuma A; Gojo S
    Sci Rep; 2020 Jul; 10(1):10821. PubMed ID: 32616755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of chemically modified oligonucleotides targeting a pathogenic mutation in human mitochondrial DNA.
    Tonin Y; Heckel AM; Dovydenko I; Meschaninova M; Comte C; Venyaminova A; Pyshnyi D; Tarassov I; Entelis N
    Biochimie; 2014 May; 100():192-9. PubMed ID: 23994754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of mitochondria-targeted endonucleases to manipulate mtDNA.
    Bacman SR; Williams SL; Pinto M; Moraes CT
    Methods Enzymol; 2014; 547():373-97. PubMed ID: 25416366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensive pathogenicity of mitochondrial heteroplasmy in healthy human individuals.
    Ye K; Lu J; Ma F; Keinan A; Gu Z
    Proc Natl Acad Sci U S A; 2014 Jul; 111(29):10654-9. PubMed ID: 25002485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.